New CDC director: We can end AIDS epidemic within 7 years

In his first all-staff meeting as director of Centers for Disease Control and Prevention (CDC), Robert Redfield, MD, predicted the U.S. could end the AIDS epidemic with tools already available. He also committed the agency’s policies to be rooted in scientific evidence. 

As reported by STAT, Redfield’s bold AIDS prediction is “possible” with existing resources like condoms and broader use of available antiviral drugs.

“I think it could be done in the next three to seven years, if we put our mind to it,” he said at the agency’s main Atlanta campus on March 28.

Redfield has spent decades researching AIDS, including some controversial positions which earned him criticism from Democrats when he was rumored to be the new pick to run the CDC. He was a principal investigator on an experimental AIDS vaccine and was accused of misrepresenting data on the treatment’s effectiveness. He also once advocated for segregating HIV-positive members of the military and mandating HIV testing during physical exams and hospitalizations.

During the talk, where Redfield answered a pre-screened set of questions from CDC employees, he mentioned he’s a strong supporter of vaccines and stressed the importance of basing CDC policy on scientific evidence—something which his predecessor’s critics doubted when it was reported the agency had “banned” certain words from budget documents.

“We’re not an opinion organization. We’re a science-based, data-driven organization. That’s why CDC has the credibility around the world that it has,” Redfield said.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.